1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
IPCA Laboratories Limited

IPCA Laboratories Limited

1,903.50
INR
-15.40
(-0.80%)
54.21EPS
32.95P/E
431.55BMarket Cap
Nov 09Next Earn
IPCA Laboratories Limited
NSE:IPCALAB
(National Stock Exchange of India)

Recent

price

1,903.50

P/E

ratio

32.95

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
75.75
92.44
110.23
128.65
123.48
113.63
122.56
127.04
146.14
180.43
211.86
227.29
244.65
300.44
349.01
376.92
399.14
Revenue per Share
10.48
10.96
12.85
18.95
10.27
3.81
7.71
9.49
17.61
24
45.01
34.85
18.58
21.57
29.08
44.98
51.63
Basic EPS, GAAP
0.77
3.7
6.32
5.65
-3.57
18.29
5.77
8.1
12.68
10.45
28.77
14.86
12.27
21.05
21.51
19.16
- -
Free Cash Flow per Basic Share
1.75
1.85
1.85
2.62
1.46
0.61
0.01
0.61
0.61
4.82
4.01
4
4
2
4
2.07
- -
Dividend per Share
41.41
49.83
61.56
77.64
87.03
89.51
97.28
106.52
123.56
143.55
185.32
215.36
230.27
249.59
273.88
317.84
- -
Book Value per Share
41.02
48.48
59.39
74.46
83.03
85.25
93.22
101.35
114.69
135.68
178.98
207.24
222.49
240.4
265.87
310.06
- -
Tangible Book Value per Share
251
252
252
252
252
252
252
252
253
253
253
254
254
254
254
254
254
Basic Weighted Avg Shares
18,998
23,306
27,812
32,470
31,166
28,680
30,934
32,066
36,922
45,587
53,660
57,665
62,069
76,224
88,546
95,625
101,256
Sales/Revenue/Turnover
17.02
19.44
19.49
22.05
11.88
6.12
8.64
8.84
14.49
16.34
24.56
18.43
11.35
12.26
15.31
17.05
17.8
Operating Margin (%)
558
671
867
1,031
1,796
1,633
1,730
1,777
1,824
2,105
2,092
2,324
2,616
3,572
3,978
4,181
4,289
Depreciation Expense
2,628
2,762
3,243
4,782
2,592
962
1,945
2,394
4,448
6,063
11,400
8,841
4,713
5,474
7,377
11,411
13,098
Net Income, GAAP
23.01
24.19
28.6
24.17
28.23
17.52
25.77
17.59
19.08
18.32
17.29
19.79
33.99
37.2
30.38
24.24
23.98
Effective Tax Rate (%)
13.83
11.85
11.66
14.73
8.32
3.35
6.29
7.47
12.05
13.3
21.25
15.33
7.59
7.18
8.33
11.93
12.94
Profit Margin (%)
4,583
5,699
7,635
8,100
6,831
6,520
7,859
9,379
12,803
15,293
22,764
29,913
33,835
31,833
38,823
40,699
- -
Working Capital
1,946
3,302
3,662
2,940
4,987
4,843
3,517
2,340
1,409
1,160
174
4,067
6,689
6,203
5,941
1,960
- -
LT Debt
10,509
12,540
15,538
19,597
21,965
22,592
24,553
26,886
31,379
36,411
47,161
55,407
59,153
77,270
83,883
95,241
- -
Total Equity
17.29
20.16
18.94
22.56
8.51
4.24
6.11
7.07
12.33
15.12
23.35
14.73
6.81
6.2
7.97
11.69
- -
Return on Invested Capital (%)
20.2
18.05
17.09
20.9
9.19
3.56
6.68
7.98
13.36
16.06
25.12
15.61
7.18
7.95
7.92
11.51
- -
Return on Capital (%)
27.43
23.96
23.1
27.22
12.47
4.32
8.25
9.31
15.31
17.97
27.37
17.39
8.34
8.99
11.11
15.2
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
6,128
- -
LT Borrowings
- -
1,091
- -
LT Finance Leases
- -
869
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
254
254
254
Market Capitalization
359,981
406,231
431,551

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
63,769
- -
Cash, Cash Equivalents & STI
- -
11,956
- -
Accounts Receivable, Net
- -
20,143
- -
Inventories
- -
27,310
- -
Total Current Liabilities
- -
23,069
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
6,128
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.74%
15.4%
13.54%
Free Cash Flow
18.41%
-0.58%
-10.95%
Net Income, GAAP
37.18%
7.29%
54.69%
Sales/Revenue/Turnover
12.99%
12.42%
8%
Total Cash Common Dividend
- -
- -
-48.35%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
20,926
23,549
22,454
22,467
88,546
2026
23,089
25,565
23,925
23,885
95,625
2027
27,881
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
7.58
9.05
9.78
2.67
29.08
2026
9.19
11.14
12.86
11.79
44.98
2027
15.84
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
4
2026
- -
- -
- -
- -
2.07
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Ipca Laboratories Limited (IPCALAB.NS) manufactures and markets a broad portfolio of pharmaceutical products, including active pharmaceutical ingredients (APIs), generic formulations, and branded generics across therapeutic categories such as anti-malarials, cardiovasculars, anti-infectives, anti-diabetics, pain management, anti-hypertensives, neuropsychiatry, gastro-intestinals, and vitamins and minerals; it also produces drug intermediates and provides contract research and manufacturing services (CRAMS). The company operates manufacturing facilities in India and exports to over 100 countries, targeting both regulated markets like the US and Europe as well as emerging markets in Africa, Asia, and Latin America. Founded in 1949 and headquartered in Mumbai, India, Ipca maintains subsidiaries including Ipca Pharma Nigeria Ltd and facilities approved by USFDA, EDQM, WHO, and other global regulators. In recent developments, Ipca launched new generic products including Sitagliptin Phosphate tablets for the US market in 2024 and expanded its anti-malarial portfolio with Artemisinin-based combination therapies amid global demand surges; it also formed a strategic partnership with Cipla Ltd for co-marketing select products in India and completed a INR 500 crore qualified institutional placement (QIP) funding round in early 2025 to support capacity expansion and R&D investments.